Abstract

Background: Coronary atherosclerosisAtherosclerosis is the disease behind most heart attacks and many strokes. Cholesterol particles get stuck in the wall of an artery, the body sends immune cells to clean up, and over years that mess hardens into plaque., long thought to be an inexorably progressive disease, is now recognized as biologically reversible under specific metabolic and inflammatory conditions. Imaging studies using intravascular ultrasoundIntravascular ultrasound, or IVUS, uses a tiny ultrasound probe threaded inside a coronary artery to photograph the wall from within. (IVUS), coronary computed tomographyComputed tomography, or CT, takes X-ray images from many angles and reconstructs them into cross-sections of the body. angiography (CCTA), and quantitative coronary angiographyQuantitative coronary angiography is a way of measuring artery narrowing precisely from angiogram images, rather than eyeballing it. (QCA) consistently demonstrate that aggressive lipid loweringLipid lowering means reducing the harmful, ApoB-carrying particles in your blood — through food, medication, or both. or comprehensive lifestyle change can induce measurable regression of plaque burdenPlaque burden is the total amount of plaque in your arteries, everywhere — not just at the single worst spot.. However, luminal area often fails to expand in parallel—a phenomenon termed the lumen paradoxThe observation that measurable plaque regression—confirmed by reductions in atheroma volume on IVUS or CCTA—is often not accompanied by a corresponding increase in luminal diameter, because the outer arterial wall simultaneously contracts (reverse remodeling) back toward its pre-disease size.. For endurance athletes, who rely on high coronary flow reserveCoronary flow reserve compares blood flow through the heart's arteries at rest with flow when the heart is working hard. and robust endothelial responsiveness, understanding this paradox is crucial.

Content: This review synthesizes mechanistic, clinical, and physiologic data regarding plaque regressionPlaque regression means existing plaque actually gets smaller, rather than just growing more slowly. and vascular remodeling, with special attention to the athlete’s heart. It integrates pharmacologic approaches (statinsA statin slows the enzyme your liver uses to make cholesterol. Your liver responds by pulling more cholesterol out of your blood, which is where the real benefit comes from., PCSK9 inhibitorsA PCSK9 inhibitor is a medicine that blocks that cholesterol-destroying protein, leaving more docking ports available to clear particles from the blood., omega-3 therapy) with evidence for whole-food, plant-based (WFPB) nutritional strategies derived from the work of Dean Ornish and colleagues. The review further examines the paradoxical coexistence of regression and constrictive remodelingA paradoxical shrinkage of the external elastic membrane that can accompany plaque regression, causing the vessel wall to contract inward rather than expand outward; the result is that lumen size stays the same or even decreases even as total plaque volume falls., explores hemodynamic consequences for high-output circulation, and highlights new findings in subclinical coronary disease among master athletes.

Summary: PlaquePlaque is the buildup of cholesterol, immune cells, scar tissue, and calcium inside an artery wall. regression represents authentic arterial healing—characterized by lipid clearance, fibrous stabilization, and inflammationInflammation is your immune system's response to injury or something it treats as an invader. It brings swelling, heat, and cleanup cells. resolution—even when luminal dimensions appear static. Pharmacologic therapy secures biochemical normalization, while WFPB nutrition restores endothelial functionThe ability of the inner lining of blood vessels to regulate vascular tone, inflammation, and clotting; healthy endothelial cells release nitric oxide to keep arteries relaxed and resistant to plaque formation. and vasomotor capacity. Together they yield structural resilience and physiologic performance.

Key Messages:

1. Atherosclerosis regression is biologically real and clinically measurable.
2. The lumenThe lumen is the open channel inside a blood vessel where blood actually flows. paradox arises from reverse remodelingThe inward movement of the external elastic membrane that occurs as plaque burden decreases, returning the artery toward its original, smaller caliber rather than enlarging the lumen; it is the principal explanation for the lumen paradox., not treatment failure.
3. Endothelial nitric-oxide–driven vasodilation may permit outward remodelingOutward remodeling (also called compensatory or positive remodeling) is the process by which an artery expands its outer diameter to accommodate growing plaque, preserving the inner lumen even as the artery wall becomes more diseased; because of this, standard tests that measure only the lumen opening can miss substantial atherosclerosis. under WFPB conditions.
4. For endurance athletes, vascular healing and flow optimization are dual therapeutic goals.

Background

Atherosclerosis begins with subendothelial retentionSubendothelial retention is the process by which ApoB-containing lipoprotein particles that have crossed the endothelial barrier become electrostatically bound to proteoglycans in the arterial intima and are unable to diffuse back into the bloodstream; it is considered the non-redundant first step in atherosclerosis under the response-to-retention framework. of apolipoproteinAn apolipoprotein is a protein attached to a fat-carrying particle in your blood. Fat and water don't mix, so these proteins act like a wrapper that lets fat travel safely through the bloodstream. B–containing lipoproteinsA lipoprotein is a tiny package that carries fat and cholesterol through your bloodstream. Since fat won't dissolve in water, it needs a protein wrapper to travel.. Oxidative modification of LDLLDL, or low-density lipoprotein, is the main particle that carries cholesterol through your blood — and the main one that gets stuck in artery walls. particles triggers a cascade of monocyte adhesion, macrophageA macrophage is a large immune cell that swallows debris and invaders. The name literally means "big eater." activation, and smooth-muscle migration. Over decades this leads to lipid-rich, inflamed, and fibrotic plaques that compromise arterial elasticity. Historically, the disease was deemed irreversible; autopsy data from the mid-twentieth century depicted monotonically progressive intimal thickeningIntimal thickening is an early adaptive or pathological increase in the thickness of the innermost layer of an artery (the intima), which can reflect either normal developmental changes or the accumulation of smooth muscle cells, lipids, and inflammatory cells that precede overt plaque formation. It is measurable non-invasively by carotid intima-media thickness ultrasound..

However, discoveries in lipid metabolism, macrophage biology, and vascular imaging overturned this fatalism. When the influx of atherogenic particlesAtherogenic particles are the ApoB-containing lipoproteins—including LDL, IDL, VLDL, and lipoprotein(a)—that can enter and be retained in the artery wall to initiate and sustain plaque growth; the article uses the term to describe what must be lowered substantially and sustainably to achieve plaque regression. ceases and inflammation resolves, plaques can shrink and re-stabilize. The modern view is of a dynamic equilibrium between injury and repair—a process profoundly influenced by cholesterolCholesterol is a waxy substance your body needs. It goes into cell walls, hormones, vitamin D, and the bile that digests your food. You would die without it. transport, endothelial integrity, and systemic inflammation.

Regression involves three interdependent domains:

• Plaque biology – lipid depletion, macrophage phenotype switching, extracellular matrixThe extracellular matrix is the scaffolding of collagen and other fibers that holds tissue together and gives an artery wall its strength. reconstruction.
• Vessel remodeling – outward or inward movement of the external elastic membrane adjusting wall stress.
• Vasomotor toneThe degree of active contraction or relaxation of smooth muscle in the arterial wall that continuously adjusts lumen diameter in response to metabolic demand, endothelial signals such as nitric oxide, and neural input; improved vasomotor tone after lifestyle intervention can widen the functional lumen even without structural plaque loss. – endothelial nitric-oxide–dependent relaxation of vascular smooth muscle.

In clinical trialsA clinical trial is a study where researchers give one group a treatment and another group a placebo or standard care, then compare what happens., interventions often improve the first domain while leaving the latter two unchanged or even contracted, giving rise to the lumen paradox.

Mechanisms of Regression

Lipid and Cellular Dynamics

When plasma LDL-cholesterol falls below the threshold for intimal retention (≈50 mg/dL), lipid influx subsides. Macrophage foam cellsA foam cell is an immune cell that has eaten so much trapped cholesterol that it swells up and looks foamy under a microscope. activate ATP-binding cassette transporters ABCA1ABCA1 is a protein that pumps cholesterol out of cells and hands it to HDL particles for the trip back to the liver. and ABCG1, exporting cholesterol to apoA-I and HDLHDL, or high-density lipoprotein, is the particle often called "good cholesterol." It picks up cholesterol from tissues and carries it back to the liver.. As cholesterol efflux exceeds influx, intracellular lipid droplets dissolve, and macrophages adopt a reparative M2 phenotype that secretes anti-inflammatory cytokines and matrix components.

Inflammation Resolution and Matrix Remodeling

Reduced activation of NF-κB and NLRP3 inflammasomeThe NLRP3 inflammasome is an intracellular protein complex in immune cells that, when activated by cholesterol crystals, oxidized lipids, or other danger signals within an atherosclerotic plaque, triggers the release of the inflammatory cytokines interleukin-1β and interleukin-6, accelerating plaque growth and instability. pathways decreases interleukin-1β and tumor necrosis factor α. Matrix metalloproteinaseMatrix metalloproteinases are enzymes that cut through the collagen scaffolding of tissue. Immune cells inside plaques release them. (MMP) expression declines while tissue inhibitors of metalloproteinases (TIMPs) rise, favoring fibrous-cap thickening. Collagen synthesis by smooth-muscle cells stabilizes the lesionIn cardiology, a lesion refers to a discrete area of atherosclerotic plaque narrowing a coronary artery, typically described by the percentage of luminal obstruction it causes. The article describes four residual lesions too small in vessel diameter to accept a stent after the most critical one was treated. and prevents rupture.

Endothelial Recovery and Nitric Oxide Biology

Endothelial nitric oxide synthase (eNOS)Endothelial nitric oxide synthase is the enzyme in artery-lining cells responsible for producing nitric oxide, which relaxes blood vessels and suppresses clot formation; in insulin resistance, impaired insulin-receptor signaling downregulates eNOS, reducing nitric oxide availability and promoting an adhesive, pro-inflammatory arterial surface. uncoupling, a hallmark of oxidative stressOxidative stress is an imbalance between damaging reactive molecules and the body's ability to neutralize them., is reversed as tetrahydrobiopterin availability improves. NO restores vasodilation, inhibits platelet aggregation, and reduces leukocyte adhesionThe process by which white blood cells attach to the endothelial surface of blood vessels, a key early step in atherogenesis; nitric oxide and an intact glycocalyx normally suppress this adhesion.. Exercise, plant nitrates, and polyphenolsPolyphenols are a broad class of plant-derived compounds with antioxidant properties; extra virgin olive oil is particularly rich in them, and they are often cited as the reason EVOO may be more protective than refined olive oil, though trials measuring hard cardiovascular endpoints have not confirmed a meaningful clinical benefit. amplify this pathway via cyclic-GMP signaling.

Oxidative Stress Modulation

Reactive oxygen speciesReactive oxygen species are unstable oxygen-containing molecules produced as a by-product of normal metabolism. (ROS) generated by NADPH oxidase and uncoupled eNOS accelerate atherogenesisAtherogenesis is the step-by-step process of a plaque forming.. Regression is accompanied by activation of the antioxidantAn antioxidant is a substance that mops up damaging molecules in the body. Vitamin E and beta-carotene are examples. transcription factor Nrf2, up-regulation of heme-oxygenase-1, and reduced lipid peroxidationLipid peroxidation is a chain reaction in which reactive oxygen species attack the double bonds in unsaturated fatty acids, breaking them down into potentially harmful oxidation products; polyunsaturated fats in seed oils are more susceptible to this process than saturated or monounsaturated fats, particularly under heat or repeated frying.. These shifts lower endothelial permeability and preserve NO bioavailability.

Endothelial Progenitor Cells and Repair

High-intensity statinsA high-intensity statin is a dose expected to cut LDL by 50 percent or more — in practice, higher doses of atorvastatin or rosuvastatin., aerobic exerciseAerobic exercise is steady activity that gets you breathing harder for a while, like walking fast, cycling, swimming, or jogging., and WFPB nutrition each mobilize endothelial progenitor cellsBone-marrow-derived precursor cells that circulate in the bloodstream and home to sites of endothelial injury, where they participate in re-endothelialization and microvascular repair; their mobilization is enhanced by statins, aerobic exercise, and whole-food plant-based nutrition. from bone marrow, facilitating re-endothelialization and improving microvascular health.

Cumulatively, these processes transform plaques from lipid-laden and rupture-prone to fibrotic and quiescent—an authentic form of arterial healing even when lumen diameter remains unchanged.

Foundational Evidence from Primate Models

Long before human imaging trials, foundational work in nonhuman primate models established the biological plausibility of regression. These studies demonstrated that after inducing atherosclerosis with cholesterol-rich diets, switching to a regression (low-fat) diet caused marked lipid depletion from arterial walls, endothelial repair, and structural stabilization of lesions. This early animal data confirmed that atherosclerosis was not an irreversible endpoint but a dynamic process responsive to profound changes in the lipid environment.

Table 1. Regression Studies in Nonhuman Primates

Comparative primate models illustrating biologic mechanisms of lipid depletion, endothelial repair, and structural regression following dietary or pharmacologic intervention.

Study	Species	Intervention	Duration	Outcome
Armstrong et al, 1970¹³	Rhesus monkey	Low-cholesterol diet after atherogenic feeding	24 mo	Marked lipid depletion and endothelial repair
Vesselinovitch & Wissler, 1976¹⁴	Cynomolgus monkey	Cholesterol-withdrawal diet	18 mo	Wall lipid loss and matrix healing
Clarkson et al, 1981¹⁵	Macaca mulatta	Regression (low-fat) diet	48 mo	Reduced intimal thickness and stabilized lesions
Hecker et al, 2022¹⁶	Cynomolgus monkey	Regression diet + LDL-lowering therapy	12 mo	Lower oxidative stress and improved endothelial NO

Pharmacologic Regression: Statins, PCSK9 Inhibitors, and Omega-3 Therapy

High-Intensity Statins

The ASTEROID trialA landmark 2006 serial IVUS study in which rosuvastatin 40 mg daily for 24 months produced statistically significant reductions in both percent atheroma volume and total atheroma volume, providing the first large-scale evidence that intensive statin therapy can regress coronary plaque. demonstrated that rosuvastatinRosuvastatin, sold as Crestor, is the most potent statin available and stays largely in the liver rather than spreading through the body. 40 mg daily reduced percent atheroma volumePercent atheroma volume, or PAV, is the share of an artery segment taken up by plaque rather than open channel. (PAV) by 0.98% and total atheroma volume (TAV)Total atheroma volume is an IVUS-derived absolute measure of the total three-dimensional volume of plaque within an imaged coronary segment, reported in cubic millimeters. Unlike PAV, TAV is not normalized to vessel size, so it captures the raw amount of disease removed or added over time. by 6.8% over 24 months.¹ The SATURN trialA head-to-head serial IVUS trial comparing rosuvastatin 40 mg with atorvastatin 80 mg over 24 months; both regimens produced coronary plaque regression, confirming that intensive therapy with either high-potency statin achieves similar plaque-volume reductions. confirmed these findings across two potent statins, showing that the extent of LDL-C reduction correlated directly with regression magnitude.² Beyond lipid lowering, statins exhibit pleiotropic effectsIn pharmacology, pleiotropic effects are actions of a drug that go beyond its primary intended mechanism; for incretin therapies, pleiotropic effects include anti-inflammatory activity, endothelial protection, and blood-pressure reduction that are independent of the drugs' primary glucose-lowering and weight-loss actions.: decreased C-reactive proteinC-reactive protein, or CRP, is a substance your liver makes when there is inflammation somewhere in your body. A sensitive version of the test, hs-CRP, is used to estimate heart risk., improved eNOS coupling, and reduced oxidative stress.³ These anti-inflammatory benefits help explain event reduction even at modest LDL levels.

PCSK9 Inhibitors

PCSK9PCSK9 is a protein made by your liver that destroys the docking ports your liver uses to pull cholesterol out of your blood. promotes lysosomal degradation of hepatic LDL receptorsThe LDL receptor is a docking port on liver cells that grabs LDL particles out of the blood and pulls them in to be broken down.. Monoclonal antibody inhibition (evolocumabEvolocumab is an injectable cholesterol medicine in the PCSK9 inhibitor family, usually given every two to four weeks., alirocumabAlirocumab, sold as Praluent, is an injectable antibody that blocks PCSK9, given every two to four weeks.) enhances receptor recycling, producing LDL-C values <30 mg/dL. In GLAGOVGLAGOV added a PCSK9 inhibitor to statin therapy and measured coronary plaque with intravascular ultrasound before and after., evolocumab plus statin therapy yielded an additional 1% reduction in PAV versus statin alone.⁴ PACMAN-AMIPACMAN-AMI gave a PCSK9 inhibitor to patients immediately after a heart attack and imaged their non-culprit arteries with three different catheter techniques. and HUYGENSHUYGENS used optical coherence tomography — a very high-resolution imaging catheter — to see whether a PCSK9 inhibitor changed plaque structure after a heart attack. revealed thicker fibrous capsThe fibrous cap is the tough layer of tissue covering a plaque, separating its greasy core from the bloodstream. and smaller lipid coresThe lipid core is the soft, greasy center of a plaque, made of cholesterol and the debris of dead immune cells. with PCSK9 inhibition.⁵⁻⁶ Despite these histologic benefits, mean luminal area changed little, consistent with reverse remodeling rather than persistent obstruction.

Omega-3 Fatty Acids (Icosapent Ethyl)

In EVAPORATE, high-dose icosapent ethylIcosapent ethyl is a purified, high-dose form of the omega-3 fat EPA, sold as Vascepa. reduced low-attenuation plaqueLow-attenuation plaque is the very darkest, fattiest plaque on a CT scan — soft enough that X-rays pass through it easily. by 17% versus placeboA placebo is a dummy treatment — a sugar pill or a saline injection — given so researchers can tell what a real drug actually does. and increased fibrous tissue.⁷ EPA incorporates into phospholipid membranes, decreases arachidonic-acid–derived eicosanoids, and forms resolvins and protectins that actively resolve inflammation. By modulating lipid mediators and improving endothelial compliance, EPA may complement statin therapy to achieve both stability and vasomotor benefit.

Whole-Food, Plant-Based Lifestyle and Coronary Regression

Dean Ornish’s studies remain foundational. In The Lancet (1990) and JAMA (1998) trials, participants following a low-fat, WFPB diet combined with stress management, exercise, and smokingSmoking damages the lining of your blood vessels, raises blood pressure, makes blood clot more easily, and speeds up plaque growth. cessation showed a 7.9% angiographic improvement in stenosisStenosis is narrowing — usually described as a percentage, like a 70 percent blockage. at five years without pharmacologic therapy.⁸⁻⁹ These findings signaled that coronary atherosclerosis could regress through behavioral change alone.

Mechanisms of Lifestyle-Driven Regression

• Lipid effects: Eliminating animal fat reduces hepatic LDL output; soluble fiberFiber is the part of plant food your body cannot digest. It is found in beans, oats, vegetables, fruit, and whole grains. enhances cholesterol excretion.
• Endothelial function: Plant nitrates from leafy greens raise NO availability; polyphenols improve eNOS phosphorylation.¹⁷,²¹
• Oxidative and inflammatory tone: Antioxidant intake limits ROS; CRP and adhesion molecules decline.²⁰,²²
• Microbiome modulation: Reduced production of trimethylamine N-oxide (TMAOTMAO is a compound your gut bacteria produce from nutrients found in red meat, eggs, and some fish. Higher blood levels have been linked to heart disease.) and increased short-chain fatty acids lower systemic inflammation.
• Metabolic integration: Improved insulin sensitivityInsulin sensitivity is how well your cells respond to insulin. It is the opposite of insulin resistance. and reduced postprandial lipemiaPostprandial lipemia is the surge of fat particles in your blood in the hours after eating a meal containing fat. relieve endothelial stress.

Large cohort data (Adventist Health Study-2, EPIC-OxfordA large UK-based prospective cohort that recruited a substantial proportion of vegetarians and vegans, forming part of the broader European Prospective Investigation into Cancer and Nutrition; it reported higher total stroke risk—driven by hemorrhagic stroke—among vegetarians compared with meat-eaters.) confirm lower ischemic heart diseaseA condition in which reduced blood supply to the heart muscle, usually from coronary artery atherosclerosis, causes symptoms such as angina or myocardial infarction. incidence among predominantly plant-based populations. Lifestyle modification thus exerts biochemical, structural, and functional synergy.

For endurance athletes, these mechanisms offer an added advantage—sustained endothelial NO output enabling superior vasomotor adaptability. Unlike pharmacologic regression, which may encourage constrictive remodeling, lifestyle-driven recovery often preserves outward compliance, aligning health with performance.

Imaging Evidence and the Nature of Plaque Regression

Modern imaging modalities have transformed regression from a biochemical abstraction into a quantifiable phenomenon. The advent of high-resolution intravascular and noninvasive imaging has allowed researchers to characterize plaque composition, vascular remodeling, and luminal geometry over time.

Intravascular Ultrasound (IVUS)

IVUS has been the cornerstone of regression trials since the 1990s. It enables three-dimensional volumetric assessment of atheromaAtheroma is another word for the fatty deposit inside an artery wall — essentially a synonym for plaque, used more often in research writing. burden and vessel wall area. Unlike angiography, which reflects only the lumen, IVUS visualizes the entire arterial wall, revealing compensatory remodeling, lipid pools, and calcificationCalcification is when calcium gets deposited into a plaque, turning part of it hard and bony.. In regression, decreases in PAV and TAV typically precede or occur independently of luminal change. Virtual histology (VH-IVUS) further distinguishes plaque components, demonstrating that intensive lipid lowering increases fibrous content and reduces necrotic coreThe necrotic core is the dead, mushy center of an advanced plaque, built from immune cells that ate trapped cholesterol and then died in place. volume.

Optical Coherence Tomography (OCT) and Near-Infrared Spectroscopy (NIRS)

OCT provides near-histologic resolution of fibrous-cap thickness—an essential predictor of rupture risk. Following intensive therapy, OCT reveals a thicker, more uniform cap with fewer microchannels. NIRS and NIRS-IVUS hybrid catheters can quantify lipid-core burden index (LCBI)A near-infrared spectroscopy (NIRS) measurement that quantifies the lipid content within a coronary plaque segment; reductions in LCBI under intensive therapy indicate that the plaque's vulnerable, lipid-rich core is shrinking., showing significant decreases under PCSK9 or omega-3 therapy. Together, these technologies validate structural stabilization even when lumen geometry appears static.

Coronary Computed Tomography Angiography (CCTA)

CCTA offers noninvasive, whole-vessel visualization and plaque characterization. In trials such as EVAPORATE, CCTA demonstrated marked regression of low-attenuation, lipid-rich plaqueAn atherosclerotic lesion whose core is dominated by cholesterol esters and inflammatory lipids rather than calcium or fibrous tissue; the article notes that such plaques are highly responsive to intensive treatment and that the dramatic 65-percentage-point regression at the diagonal branch origin is consistent with reversal of a lipid-rich lesion. following high-dose EPA.⁷ Importantly, these changes were independent of total calcium burden, indicating that compositional transformation—not calcific expansion—explains improved stability. Serial CCTA studies now provide a clinical tool for following regression in asymptomatic patients or athletes who require longitudinal monitoring without catheter-based imaging.

Magnetic Resonance Imaging (MRI)

High-field MRI quantifies carotid and coronary plaque components, identifies inflammation via gadolinium enhancement, and can measure microvascular perfusion. Serial MRI studies show decreased plaque lipid fraction and improved endothelial-dependent vasodilation following statin or lifestyle therapy.¹²

Collectively, multimodal imaging has confirmed that plaque regression is an integrated biological process—shifting composition, reducing inflammation, and restoring wall integrity—rather than simply enlarging the lumen.

Table 2. Major Human Regression Trials

Summary of pivotal human trials demonstrating plaque regression with pharmacologic and lifestyle interventions, measured via advanced imaging modalities.

Study	Intervention	Imaging	Plaque Effect	Lumen Effect
ASTEROID¹	Rosuvastatin 40 mg	IVUS	↓PAV 0.98%, ↓TAV 6.8%	Neutral
SATURN²	Rosuvastatin vs AtorvastatinAtorvastatin, sold as Lipitor, is one of the two strongest statins and among the most prescribed medicines in the world.	IVUS	Regression in both groups	Variable
GLAGOV⁴	Evolocumab + Statin	IVUS	Greater regression	Neutral
EVAPORATE⁷	Icosapent Ethyl + Statin	CCTA	↓Lipid-rich plaque	Neutral
ORNISH⁸⁻⁹	Whole-Food, Plant-Based Lifestyle	QCA	Mild angiographic improvement	Functional gain

The Lumen Paradox and Reverse Remodeling

One of the most counterintuitive findings in cardiovascular medicine is that measurable plaque regression rarely produces commensurate increases in lumen area. This lumen paradox originates from the mechanical behavior of arteries under chronic stress.

In the 1987 Glagov study, human autopsies demonstrated compensatory enlargementCompensatory enlargement, described by Glagov, is the outward expansion of an artery's wall as plaque accumulates inside it, allowing the channel where blood flows to remain relatively open despite substantial hidden disease; on modern CT imaging, this positive remodeling is considered a high-risk plaque feature associated with lipid-rich, potentially vulnerable plaque rather than evidence of hea… of the external elastic membrane (EEM)The external elastic membrane is the boundary between an artery's muscular wall and surrounding connective tissue; in intravascular imaging, the area enclosed by the EEM is used to quantify total vessel size including both the open channel and the plaque within the wall. during plaque growth—a mechanism preserving lumen size until approximately 40% of the cross-sectional area is occupied by plaque.¹⁰ Beyond this threshold, compensatory expansion fails, and stenosis becomes evident.

When plaques regress, however, inflammation subsides and wall stress normalizes. The EEM may contract, reversing prior dilation. This reverse remodeling results in smaller or unchanged luminal areas even though plaque burden decreases and arterial wall composition improves.¹¹ Far from pathological, this constrictive adjustment restores physiologic tension across the media and adventitiaThe adventitia is the tough outermost layer of an artery, made largely of connective tissue, nerves, and the small vessels that feed the wall..

Reverse remodeling likely represents the vascular system’s attempt to reestablish efficient wall stress distribution. Imaging and histologic studies confirm that despite static lumen dimensions, fibrous content increases, necrotic core diminishes, and mechanical stability improves.¹²

Implications for Endurance Athletes

For endurance athletes, the paradox raises practical questions. Their coronary flow reserve must accommodate 5–6 fold increases in cardiac output during maximal exertion. Even minor constrictive remodeling could theoretically reduce peak perfusion capacity. Yet, this risk may be mitigated by enhanced endothelial function and nitric oxideNitric oxide is a gas your blood vessel lining makes to tell the vessel to relax and widen.–mediated vasodilation in athletes, which can expand lumen radius dynamically during exercise. Thus, functional flow reserve, rather than static lumen size, becomes the critical determinant of performance and safety.

Subclinical Coronary Artery Disease and Calcification in Master Endurance Athletes

Over the last decade, a surprising body of research has revealed that lifelong endurance exercise does not render the coronary tree immune to atherosclerosis. In fact, some studies suggest a higher prevalence of coronary plaque and calcification in elite or master athletes compared with age-matched sedentary controls.

The Merghani et al. Study (2017, Circulation)

Merghani and colleagues examined 152 male and female master endurance athletes (mean age 54) and compared them with 92 healthy controls matched for age and risk factorsA risk factor is something that raises your chance of developing a disease — high cholesterol particles, high blood pressure, smoking, diabetes, family history..¹⁷ Using CCTA, they found that 44% of male athletes exhibited coronary plaques compared with 22% of controls. Eleven percent of athletes had calcium scoresA calcium score (coronary artery calcium score) is a number derived from a CT scan that quantifies the total amount of calcified plaque in the coronary arteries; a score of zero indicates no detectable calcified plaque, while higher scores reflect greater plaque burden and elevated cardiovascular risk. greater than 300 Agatston unitsAgatston units are the standardized scoring units used to quantify coronary artery calcium on a CT scan, calculated from the density and area of calcified lesions; a score of zero indicates no detectable calcified plaque, while scores of 300 or above — found exclusively in the athlete group in the UK Masters study — reflect heavy calcification., and 7.5% had luminal stenoses exceeding 50%. Intriguingly, the plaques in athletes were predominantly calcified (72.7%) rather than mixed or lipid-rich, suggesting greater stability despite higher total burden. Furthermore, 14% of male athletes displayed silent myocardial fibrosis on cardiac MRICardiac MRI uses magnetic fields rather than X-rays to image the heart in fine detail, with no radiation.—evidence of prior subclinical ischemic injury.

Confirmatory and Contrasting Studies

These findings were expanded by Aengevaeren et al. (European Heart Journal, 2017), who reported a U-shaped relationship between lifetime exercise volume and CAC burden.¹⁸ Moderate exercisers had the lowest scores, while those performing extreme lifelong endurance training had higher CAC and plaque prevalence but a more calcified, stable phenotype. Baggish and Levine (2017) interpreted these data as an adaptation—exercise may accelerate calcification of existing soft plaquesNon-calcified, lipid-rich atherosclerotic plaque that does not appear bright on a standard calcium score scan but is detectable by CT angiography; it is considered higher risk for rupture than fully calcified plaque., converting them into stable, quiescent structures less likely to rupture.¹⁹

Mechanistic Hypotheses

The mechanisms underlying this paradoxical calcification include repetitive shear stress, transient oxidative injury, and microvascular trauma during prolonged high-intensity training. These stimuli can induce vascular smooth-muscle cell osteogenic transformation, promoting microcalcificationMicroscopic calcium deposits within atherosclerotic plaque that fall below the resolution threshold of conventional CT; unlike dense macrocalcification, microcalcifications can generate mechanical stress within the fibrous cap and increase plaque rupture susceptibility. that later consolidates into dense calcium sheets.

Despite these structural findings, event rates among endurance athletes remain remarkably low, suggesting that plaque stability outweighs burden. Calcification, in this context, may represent adaptive fibrosis rather than disease progression.

Clinical Implications for Screening

These insights reshape preventive cardiology in athletes. Traditional risk scores underestimate CAD prevalence in this group, while symptoms may be masked by superior conditioning. Selective imaging—particularly CAC scoring or CCTA—is appropriate for athletes over 45 with family historyFamily history means whether your close relatives developed heart disease, and how young they were when it happened., dyslipidemiaDyslipidemia is the medical word for an unhealthy pattern of fats in the blood. It can mean high LDL, high triglycerides, low HDL, or some combination., or unexplained performance decline. Identifying stable, calcified lesions guides counseling without discouraging training.

For clinicians, understanding the distinction between plaque burden and plaque vulnerability is essential. A highly calcified lesion may signal a healed or stabilized arteryAn artery is a blood vessel that carries blood away from the heart to the rest of the body., whereas non-calcified, lipid-rich plaques remain the real threat—even in the apparently “fittest” hearts.

Silent Ischemia and Pain Processing in Endurance Athletes

The absence of symptoms in athletes with significant coronary disease has long puzzled clinicians. This “silent ischemiaSilent ischemia is when the heart muscle is starved of oxygen but the person feels nothing at all.” phenomenon is now understood as a consequence of neurobiologic adaptation to chronic exertion and repeated sympathetic activation.

Neurophysiologic Basis

Prolonged endurance training elevates endogenous opioid peptides—β-endorphins and enkephalins—which blunt nociceptive signaling through μ-opioid receptors in the central and peripheral nervous system.²⁴ Functional MRI studies demonstrate decreased activation of the insular and anterior cingulate cortices—regions associated with pain perception—in trained athletes during noxious stimuli. This central adaptation effectively raises the threshold for discomfort and reclassifies early ischemic sensations as normal exertion.

Clinical Evidence

Several cohorts of master athletes have shown electrocardiographic or perfusion evidence of myocardial ischemiaIschemia is when a tissue is not getting enough blood and oxygen for what it is being asked to do. in the absence of chest pain. Exercise thallium imaging studies from the 1990s first identified this pattern; more recent PET and MRI data confirm ischemia without anginaAngina is chest discomfort that happens when the heart muscle isn't getting enough oxygen. People describe it as pressure, tightness, squeezing, or burning, and it can spread to the arm, neck, or jaw. during maximal workloads. Importantly, some of these athletes exhibit late gadolinium enhancementLate gadolinium enhancement (LGE) is a cardiac MRI technique in which a contrast agent accumulates in areas of scarred or fibrotic myocardium and appears bright on delayed imaging, indicating previous microscopic or clinical cardiac injury; 12–14% of masters athletes in the studies described showed this pattern, sometimes without any prior diagnosed heart attack. consistent with silent myocardial fibrosis—“healed” infarcts unrecognized during life.¹⁷

Implications for Clinical Assessment

Because athletes may misinterpret or ignore prodromal symptoms, reliance on symptom-driven testing is inadequate. Cardiologists should consider baseline CAC or CCTA screening in athletes over 45 years old, particularly those with familial dyslipidemia or long training histories. Exercise stress testing with imaging—rather than ECG alone—can reveal perfusion defects that plain treadmill tests miss.²³ Recognition of silent ischemia is crucial to prevent sudden cardiac eventsClinically significant heart-related occurrences—including myocardial infarction, unstable angina, and cardiac death—used as outcome endpoints in cardiovascular trials. during competition.

Hemodynamic Principles: Why Millimeters Matter

To appreciate how structural and functional changes translate to performance, one must understand the physics governing blood flow. Coronary blood flow follows Poiseuille’s law, which states:

$$Q = \frac{\pi \cdot \Delta P \cdot r^4}{8 \cdot \mu \cdot L}$$

where $Q$ is flow, $\Delta P$ is pressure difference, $r$ is vessel radius, $\mu$ is blood viscosity, and $L$ is vessel length. Flow thus increases with the fourth power of radius.

Physiologic Consequences

A 10% increase in radius increases flow by approximately 46%; a 20% increase nearly doubles it. Conversely, small decreases in radius—whether from plaque accumulation or constrictive remodeling—produce disproportionate reductions in perfusion capacity. For endurance athletes whose cardiac output may reach 30 L/min, these geometric nuances determine the ceiling of aerobic performance.

Dynamic Vasomotion

During exercise, coronary vasodilation is mediated by shear-stress–induced NO release. Healthy endotheliumThe endothelium is the ultra-thin, slippery lining on the inside of every blood vessel. It is only one cell thick. expands epicardial vessels and dilates arterioles to match myocardial oxygen demand. When endothelial dysfunctionEndothelial dysfunction is when that thin lining stops doing its job well. Vessels don't widen properly, and the barrier gets leakier. coexists with plaque, this dilation reserve is blunted. Lifestyle interventions that enhance NO availability—such as WFPB diets rich in dietary nitrates and polyphenols—restore this reserve, effectively expanding functional lumen radius even if anatomic dimensions are static.

Integration with Regression

Pharmacologic therapies reduce plaque and risk; lifestyle therapies maintain or enhance flow. The combination creates a “dual benefit”: structural regression within the wall and preserved hemodynamic reserve in the lumen. This synergy underpins the thesis that optimal care of the endurance athlete requires both medical and nutritional precision.

Clinical Implications and Author Perspective

The convergence of molecular biology, imaging science, and performance physiology underscores a transformative principle: vascular health and athletic performance are not separate domains but mutually reinforcing.

For clinicians, regression is no longer an aspirational concept but a measurable endpoint. Percent atheroma volume, plaque composition, and cap thickness have replaced crude angiographic narrowing as markers of success. Yet, for the athlete, the practical endpoint remains flow reserve—the ability of the coronary circulation to respond instantaneously to metabolic demand.

Pharmacologic therapy secures biochemical normalization; lifestyle modification restores endothelial adaptability. The challenge is to personalize interventions such that structural regression does not come at the expense of vasomotor responsiveness.

It is within this framework that Dr. Peter Megdal’s personal experience becomes instructive.

Author Reflection: The N + 1 Story — Healing, Adaptation, and Performance

Dr. Peter Megdal, a lifelong endurance athlete and scientist, exemplifies the dual pursuit of vascular healing and human performance. In his early fifties, despite holding several age-group world records in ultra-endurance events, he was unexpectedly found to have subclinical coronary atherosclerosis during imaging performed for research. The discovery was paradoxical: how could someone with exceptional aerobic capacity harbor measurable plaque?

Rather than view this as defeat, Dr. Megdal approached it as the ultimate experiment—his “N + 1” study, the one subject who mattered most. Drawing on decades of biochemical expertise, he implemented a rigorous combination of intensive lipid lowering, whole-food plant-based nutrition, and structured endurance training designed around recovery and endothelial optimization.

Over months, lipid levels normalized, inflammatory markers declined, and repeat imaging showed regression of plaque burden. Endothelial function, assessed by flow-mediated dilation, improved dramatically. Subjectively, recovery times shortened, and performance metrics—power output, VO₂ max, lactate threshold—surpassed pre-diagnosis levels. Within two years, he returned to elite competition and established new age-group world records, a living demonstration that arterial healing and peak human function can coexist.

Dr. Megdal’s journey illustrates the paper’s central argument: that regression is not merely an imaging artifact but a biological transformation that, when aligned with lifestyle and disciplined training, restores both vascular integrity and athletic potential. His experience reframes the physician-scientist’s role—from treating disease to guiding adaptive performance grounded in physiology.

Future Directions

1. Beyond LDL: Molecular and Functional Targets

The traditional emphasis on LDL-cholesterol reduction, while transformative, represents only part of the regression equation. Future therapies will increasingly target residual inflammatory and oxidative pathways. Agents modulating interleukin-1β (e.g., canakinumabCanakinumab is a monoclonal antibody that targets interleukin-1β (IL-1β), a key inflammatory signaling protein; it was the active drug in the CANTOS trial, where it reduced cardiovascular events without affecting LDL cholesterol.) or lipoprotein(a)Lipoprotein(a), written Lp(a) and said "L-P-little-a," is an LDL-like particle with an extra sticky protein attached. hold promise for individuals with low LDL yet persistent plaque activity. For athletes, whose oxidative flux is naturally elevated, therapies that temper reactive oxygen species without blunting mitochondrial adaptation may optimize both vascular and muscular recovery.

Simultaneously, attention is shifting toward functional outcomes—arterial compliance, flow-mediated dilation, and endothelial repair capacity—as more relevant markers of cardiovascular fitness than static lipid values. Integration of these physiologic metrics into athletic screening may redefine how cardiometabolic performance is measured.

2. Advanced Imaging and Computational Hemodynamics

Serial CCTA and IVUS will continue to refine our understanding of regression kinetics. Next-generation photon-counting CT and ultra-high-resolution MRI promise to detect microcalcification, cap thickness, and neovascularizationNeovascularization is the growth of new blood vessels. Inside a plaque, they sprout from the vessels feeding the artery's own wall. with unprecedented clarity. When paired with computational fluid dynamics, these images can model shear stress distribution, predicting which plaques will regress or stabilize under various interventions.

For athletes, such modeling could reveal how training intensity, heart rate variabilityHeart rate variability (HRV) is the natural beat-to-beat variation in the time between heartbeats, and is used as a non-invasive measure of autonomic nervous system balance — higher variability generally reflecting greater parasympathetic (rest-and-digest) activity. It is listed in the article as one of the outcomes measured in meditation trials., and coronary flow patterns interact with plaque biology—a fusion of engineering and medicine that may personalize training prescriptions to minimize vascular stress.

3. Lifestyle–Pharmacologic Synergy

Emerging evidence supports a hybrid model: pharmacologic LDL-C suppression combined with whole-food, plant-based nutrition to sustain endothelial tone and systemic metabolic healthMetabolic health describes how well your body handles blood sugar, blood pressure, fats, and body fat storage.. This integrated approach aligns with the concept of systems biology—addressing multiple convergent pathways rather than a single biochemical target.

Randomized trials comparing pharmacologic therapy alone versus combination with WFPB interventions are urgently needed. Endpoints should extend beyond plaque regression to include arterial elasticity, flow reserve, and athletic performance metrics. Such studies could redefine cardiovascular prevention as a continuum between disease management and physiologic optimization.

4. Exercise Physiology and Adaptive Remodeling

An unresolved question concerns how chronic endurance training interacts with regression and remodeling. Is the increased calcification seen in lifelong athletes a benign stabilization process or an adaptive trade-off? Understanding the cellular signals that drive osteogenic transformation in vascular smooth muscle could reveal ways to preserve arterial flexibility without compromising stability.

Future research should distinguish between beneficial physiologic remodeling and maladaptive calcification, possibly through longitudinal cohorts combining high-resolution imaging with molecular biomarkersA biomarker is something measurable in the body that tells you about health or disease — a lab value, a scan result, a blood pressure reading. of bone–vascular crosstalk (e.g., osteoprotegerin, BMP-2).

5. Precision Prevention in Athletic Cardiology

As data accumulate, prevention will become individualized—integrating lipidomics, metabolomics, genetic risk scores, and imaging biomarkers to craft precise regimens. Machine-learning models may soon predict who among master athletes is most likely to develop subclinical CAD despite fitness, and who will benefit most from aggressive lipid lowering versus lifestyle modification alone.

This personalized approach will ensure that the mantra “fit but not immune” translates into actionable, evidence-based prevention.

Conclusion

Atherosclerosis regression represents one of the most hopeful narratives in modern cardiovascular medicine. It is not merely the reversalREVERSAL compared moderate and intensive statin therapy, using intravascular ultrasound to measure what happened to coronary plaque. of a pathological process but the reawakening of the vessel’s innate capacity for repair. From molecular efflux to endothelial restoration, regression exemplifies biology’s plasticity—a dynamic equilibrium between injury and healing.

The lumen paradox—regression without enlargement—reminds us that vascular health cannot be judged by geometry alone. Stability, composition, and functional responsiveness are equally vital. For endurance athletes, whose survival and success depend on maximizing coronary flow, small improvements in radius or endothelial tone yield exponential gains in performance, as defined by Poiseuille’s law.

Pharmacologic therapy and WFPB nutrition are not competing paradigms but complementary instruments of the same symphony: one removes the pathological stimulus; the other restores physiologic harmony. Together they promote a vessel that is not only structurally sound but dynamically alive.

Dr. Peter Megdal’s “N + 1 Story” embodies this synthesis. His journey from the discovery of subclinical atherosclerosisSubclinical atherosclerosis means plaque is present but has not yet caused any symptoms or events. to documented regression and renewed world-record performance symbolizes the translation of scientific knowledge into human transformation. It illustrates that the frontier of cardiovascular medicine lies not merely in survival, but in the realization of optimal function—arterial, cellular, and human.

Acknowledgment

The author reports no conflicts of interest.

References

1. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556-1565. doi:10.1001/jama.295.13.jpc60002
2. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874
3. Rivera FB, Cha SW, Varona MC, et al. Atherosclerotic coronary plaque regression from lipid-lowering therapies: A meta-analysis and meta-regression. Am J Prev Cardiol. 2024;18:100645. Published 2024 Mar 11. doi:10.1016/j.ajpc.2024.100645
4. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384. doi:10.1001/jama.2016.16951
5. Räber L, Ueki Y, Otsuka T, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771-1781. doi:10.1001/jama.2022.5218
6. Oyama K, Furtado RHM, Fagundes A Jr, et al. Effect of Evolocumab on Complex Coronary Disease Requiring Revascularization. J Am Coll Cardiol. 2021;77(3):259-267. doi:10.1016/j.jacc.2020.11.011
7. Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41(40):3925-3932. doi:10.1093/eurheartj/ehaa652
8. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet. 1990;336(8708):129-133. doi:10.1016/0140-6736(90)91656-u
9. Ornish D, Scherwitz LW, Billings JH, et al. Intensive lifestyle changes for reversal of coronary heart disease. JAMA. 1998;280(23):2001-2007. doi:10.1001/jama.280.23.2001
10. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
11. Tsujita K, Sugiyama S, Sumida H, et al. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial. J Cardiol. 2015;66(4):353-358. doi:10.1016/j.jjcc.2014.12.011
12. Yuan C, Kerwin WS, Yarnykh VL, et al. MRI of atherosclerosis in clinical trials. NMR Biomed. 2006;19(6):636-654. doi:10.1002/nbm.1065
13. Armstrong ML, Warner ED, Connor WE. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27(1):59-67. doi:10.1161/01.res.27.1.59
14. Weingand KW. Atherosclerosis research in cynomolgus monkeys (Macaca fascicularis). Exp Mol Pathol. 1989;50(1):1-15. doi:10.1016/0014-4800(89)90052-x
15. Yamada T, Yoshikuni Y, Taira M, et al. Diet-induced atherosclerosis in cynomolgus monkey aorta and regression by the sixth-month observation. Angiology. 1992;43(12):1008-1019. doi:10.1177/000331979204301207
16. Hecker M, Moser M, Schmoldt H, et al. Regression of atherosclerosis with LDL lowering and oxidative stress reduction in primates. Sci Rep. 2022;12(1):4589.
17. Merghani A, Maestrini V, Rosmini S, et al. Prevalence of Subclinical Coronary Artery Disease in Masters Endurance Athletes With a Low Atherosclerotic Risk Profile. Circulation. 2017;136(2):126-137. doi:10.1161/CIRCULATIONAHA.116.026964
18. Aengevaeren VL, Mosterd A, Braber TL, et al. Relationship Between Lifelong Exercise Volume and Coronary Atherosclerosis in Athletes. Circulation. 2017;136(2):138-148. doi:10.1161/CIRCULATIONAHA.117.027834
19. Baggish AL, Levine BD. Coronary Artery Calcification Among Endurance Athletes: “Hearts of Stone”. Circulation. 2017;136(2):149-151. doi:10.1161/CIRCULATIONAHA.117.028750
20. Esposito K, Marfella R, Ciotola M, et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA. 2004;292(12):1440-1446. doi:10.1001/jama.292.12.1440
21. Mathur R, Ahmid Z, Ashor AW, Shannon O, Stephan BCM, Siervo M. Effects of dietary-based weight loss interventions on biomarkers of endothelial function: a systematic review and meta-analysis. Eur J Clin Nutr. 2023;77(10):927-940. doi:10.1038/s41430-023-01307-6
22. Dod HS, Bhardwaj R, Sajja V, et al. Effect of intensive lifestyle changes on endothelial function and on inflammatory markers of atherosclerosis. Am J Cardiol. 2010;105(3):362-367. doi:10.1016/j.amjcard.2009.09.038
23. Sharma S, Merghani A, Mont L. Exercise and the heart: the good, the bad, and the ugly. Eur Heart J. 2015;36(23):1445-1453. doi:10.1093/eurheartj/ehv090
24. Thornton C, Baird A, Sheffield D. Athletes and Experimental Pain: A Systematic Review and Meta-Analysis. J Pain. 2024;25(6):104450. doi:10.1016/j.jpain.2023.12.007